ProQR Receives Orphan Drug Status for F508del Therapy

More hope on the horizon for those with cystic fibrosis. New drug in development.

sixtyfiveroses

ProQR Therapeutics recently received EMA and FDA orphan drug designation for their therapy targeting Cystic Fibrosis. ProQR Therapeutics are developing an antisense oligonucleotide that targets the F508del Cystic Fibrosis mutation. This is currently in the pre-clinical stage.

This approach is different to the CFTR modulation approach (potentiators and correctors), which targets the defective protein.CF gene mutations are present in the DNA, this defect is copied into the RNA, which is copied into the protein. ProQR are targeting the Cystic Fibrosis defect at the RNA level. This means the normal CFTR protein is made from the RNA, restoring chloride transport.

Sources:EMA COMP September 2013 Report andFDA Orphan Drug Designation

View original post

Advertisements

One thought on “ProQR Receives Orphan Drug Status for F508del Therapy

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s